


TSE : 4568

Reference Data

Consolidated Financial Results for FY2009



Daiichi-Sankyo

May 12, 2010

Daiichi Sankyo Co., Ltd.
<http://www.daiichisankyo.com>

(This page is intentionally left blank)



Daiichi-Sankyo

TSE : 4568

Reference Data

Consolidated Financial Results for FY2009

[1] Summary of Income Statement	P1
[2] Currency Rate	P3
[3] Sales of Global Products	P3
[4] Overseas Sales	P4
[5] Consolidated Segment Information – Operating Segment	P4
[6] Consolidated Segment Information – Geographic Segment	P4
[7] Status of Major Companies	P5
[8] Number of Employees	P9
[9] Major Management / Financial Indicators	P10
[10] Capital Expenditure and Depreciation Expenses	P10
[11] Number of Shares Held and Shareholders by Category	P10
[12] Consolidated Balance Sheets	P11
[13] Consolidated Statements of Cash Flows	P13
[14] R&D Pipeline	P14

<Historical Data>

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.

1. Summary of Income Statement

< Daiichi Sankyo Group - Consolidated >

(Billions of yen)

	FY2009 Results						Details (YoY Changes)
	Q4		Full Year		From Jan. Forecast	YoY Changes	
Net Sales	<5.6>		<13.1>				Consolidation of Ranbaxy: ¥+108.0 bil (3 months for FY2008) Olmesartan: ¥+27.2 bil, Loxonin: ¥+8.3 billion Levofloxacin: ¥-10.5 bil, Pravastatin: ¥-5.8 bil Azor (lump sum payment received in FY2008): ¥-4.6 bil [Decrease by yen appreciation: Approx. ¥-25.0 bil]
	100.0	226.4	100.0	952.1	-7.9	110.0	
Cost of Sales	28.9	65.4	29.2	278.0	-7.0	63.6	Cost to sales ratio: +3.7Points Consolidation of Ranbaxy: +2.4Points Impact of currency fluctuation: +0.6 Points
SG&A Expenses	68.7	155.6	60.8	578.6	-0.4	39.7	
R&D Expenses	24.3	55.1	20.7	196.8	2.8	12.3	Increase in development project costs of Edoxaban, etc.
Other Expenses	44.4	100.5	40.1	381.8	-3.2	27.4	Consolidation of Ranbaxy: ¥+35.1 bil Reduction of promotional expense at subsidiaries in Europe and U.S., etc.
Operating Income	<->		<7.5>				
	2.4	5.4	10.0	95.5	-0.5	6.6	
Non-operating Income		9.1		28.2	-0.8	15.9	Gain on valuation of Ranbaxy's forex derivatives, etc.
Non-operating Expenses		2.1		20.6	-4.4	-25.4	Ranbaxy-related: Losses on valuation of forex derivatives in FY2008 Others: Decrease of exchange loss and valuation loss of synthetic stock options
Ordinary Income	<->		<86.9>				
	5.5	12.5	10.8	103.1	3.1	47.9	
Extraordinary Gains		2.1		5.9	0.9	2.1	
Extraordinary Losses		8.1		11.6	2.6	-355.6	One-time write-down of Ranbaxy's goodwill in FY2008: ¥351.3 billion
Income before taxes and minority interests	2.8	6.4	10.2	97.4	1.4	405.6	
Net Income	<-96.8>		<->				Income taxes: ¥50.0 bil (Tax rate: 51.4%) Tax rate increased mainly due to the following factors: amendment of income taxes for prior years: ¥7.5 bil non-application of R&D tax credits on parent Minority interests: ¥5.5 bil
	1.2	2.6	4.4	41.9	-3.1	257.4	

< Ranbaxy >

	FY2009 Results				
	Q4		Full Year		YoY Changes
Net Sales	<15.1>		<279.5>		
	100.0	44.5	100.0	146.7	108.0
Cost of Sales	40.6	18.1	51.4	75.4	54.9
SG&A Expenses	43.4	19.3	44.3	64.9	47.4
R&D Expenses	7.9	3.5	7.0	10.3	7.7
Other Expenses	35.5	15.8	37.2	54.6	39.6
Operating Income	<->		<->		
	16.0	7.1	4.3	6.3	5.7
Non-operating Income		8.7		21.1	19.7
Non-operating Expenses		0.7		14.5	-11.5
Ordinary Income	<->		<->		
	34.0	15.1	8.9	13.0	36.9
Extraordinary Gains		1.3		1.3	1.2
Extraordinary Losses		0.1		0.1	-0.2
Income before taxes and minority interests	36.8	16.4	9.7	14.2	38.3
Net Income	<->		<->		
	16.0	7.1	2.9	4.2	20.4

(Billions of yen)

	FY2010 Forecast						Details
	1st Half		YoY Changes	Full Year		YoY Changes	
Net Sales	<4.1>			<2.9>			Expected overseas sales: ¥507 bil Expected sales of Ranbaxy: ¥165 bil
	100.0	490.0	19.4	100.0	980.0	27.9	
Cost of Sales	29.4	144.0	6.8	29.6	290.0	12.0	
SG&A Expenses	60.4	296.0	13.5	61.2	600.0	21.4	
R&D Expenses	20.8	102.0	7.9	21.4	210.0	13.2	
Other Expenses	39.6	194.0	5.6	39.8	390.0	8.2	
Operating Income	<-1.7>			<-5.8>			
	10.2	50.0	-0.9	9.2	90.0	-5.5	
Non-operating Income / (Expense)		-2.0	-3.4		-5.0	-12.6	
Ordinary Income	<-8.2>			<-17.6>			
	9.8	48.0	-4.3	8.7	85.0	-18.1	
Extraordinary Gain / (Loss)			-1.4			5.7	
Income before taxes and minority interests	9.8	48.0	-5.7	8.7	85.0	-12.4	
Net Income	<33.7>			<7.5>			Expected net income of Ranbaxy: ¥6.0 bil
	5.1	25.0	6.3	4.6	45.0	3.1	

< Impact of Business Combination of Ranbaxy >

	FY2009 Results		
	Q4	Full Year	YoY Changes
Net Sales			
Cost of Sales			-1.8
SG&A Expenses	1.5	6.0	-11.5
R&D Expenses			-6.9
Other Expenses	1.5	6.0	-4.6
Operating Income	-1.5	-6.0	13.3
Non-operating Income			
Non-operating Expenses			
Ordinary Income	-1.5	-6.0	13.3
Extraordinary Gains	0.0	0.0	0.0
Extraordinary Losses			-351.3
Income before taxes and minority interests	-1.5	-6.0	364.6
Net Income	3.8	2.8	252.0

< Performance without Ranbaxy's Consolidation >

	FY2009 Results		
	Q4	Full Year	YoY Changes
	<3.4>		
	100.0	181.9	1.9
	26.0	47.3	10.5
	74.1	134.8	3.8
	28.4	51.6	11.4
	45.7	83.2	-7.7
	<-11.5>		
	-0.1	-0.2	-12.4
		11.8	95.2
		0.4	-3.8
		1.4	-13.9
	<-2.3>		
	-0.6	-1.1	-2.2
		11.9	96.1
		0.8	0.9
		8.1	-4.0
	-4.7	-8.5	2.7
		11.1	89.1
	<-30.2>		
	-4.6	-8.3	-15.1
		4.3	34.8

2. Currency Rate

	FY2008	FY2009		FY2010		
	Full Year Results	Original Forecast	Full Year Results	Full Year Forecast	Annual impact of one yen change in currency rate	
USD / Yen (average)	100.5	95.0	92.9	90.0	Net Sales	¥2.5 billion
					Operating Income	¥0.2 billion
EUR / Yen (average)	143.5	120.0	131.2	120.0	Net Sales	¥0.7 billion
					Operating Income	¥0.1 billion

3. Sales of Global Products

(Billions of yen)

	FY2009 Results					FY2010 Forecast	
	Q4	Full Year	From Jan. Forecast	YoY Changes	Full Year	YoY Changes	
Olmesartan <antihypertensive>	<19.0> 58.3	<12.9> 238.3	0.3	27.2	<9.1> 260.0	21.7	
Olmetec (JPN)	<12.5> 16.2	<20.0> 77.2	-0.8	12.9	<11.4> 86.0	8.8	
Rezaltas (JPN)	-	-	-	-	<->	5.0	
Benicar HCT / Benicar (US)	<11.7> 21.9	<1.8> 88.9	0.9	1.6	<0.6> 89.5	0.6	
Azor (US)	<29.7> 2.9	<47.2> 12.8	-0.2	4.1	<1.7> 13.0	0.2	
Olmetec Plus / Olmetec (EU)	<17.7> 11.4	<6.5> 39.9	-1.1	2.4	<2.7> 41.0	1.1	
Sevikar (EU)	<156.5> 2.0	<189.3> 6.3	0.8	4.1	<50.0> 9.5	3.2	
Other subsidiaries / Export, etc.	<71.4> 3.7	<19.2> 13.1	1.1	2.1	<21.8> 16.0	2.9	
Levofloxacin <synthetic antibacterial>	<-3.5> 21.8	<-10.7> 87.2	2.7	-10.5	<-19.7> 70.0	-17.2	
Cravit (JPN)	<17.5> 11.4	<1.5> 43.6	3.6	0.6	<-24.4> 33.0	-10.6	
Export, etc	<-29.5> 5.0	<-31.5> 21.3	-1.2	-9.8	<-24.8> 16.0	-5.3	
Royalty	<-8.8> 3.6	<-9.3> 14.6	0.1	-1.5	<-14.3> 12.5	-2.1	
Other subsidiaries	<-2.2> 1.8	<2.2> 7.7	0.2	0.2	<10.7> 8.5	0.8	
Pravastatin <antihyperlipidemic>	<-14.9> 10.5	<-9.6> 55.0	-1.0	-5.8	<-20.0> 44.0	-11.0	
Mevalotin (JPN)	<-14.7> 8.5	<-8.9> 46.2	-0.8	-4.5	<-19.9> 37.0	-9.2	
Other subsidiaries / Export, etc.	<-15.7> 2.0	<-12.8> 8.8	-0.2	-1.3	<-20.6> 7.0	-1.8	
Prasugrel (alliance revenue) <antiplatelet>	<-> -0.7	<-> 0.5	-	0.5			
Effient (US)	<-> -1.1	<-> 0.1	-	0.1			
Efient (EU)	<-> 0.4	<-> 0.5	-	0.4			

Forecast of prasugrel is not disclosed.

As a result of reviewing the disclosure of alliance revenue of prasugrel in this reference data, the revised amount until Q3, ¥-1 bil (Previous: ¥1.1 bil, restated as ¥0.1 bil, revised amount: ¥-1 bil) is included in the results of Q4. Consolidated net sales etc. are correctly accounted for and remain unchanged.

Total global sales of prasugrel by Eli Lilly and Company for Apr. 2009 to Mar. 2010 is approximately USD 35.5 mil, of which the U.S. sales is approximately USD 27 mil.

4. Overseas Sales

(Billions of yen)

	FY2009 Results				
	Q4	YoY Changes		Full Year	YoY Changes
Overseas sales	<12.6>	129.2	14.5	<29.2>	109.1
Overseas sales ratio		57.0%		50.7%	
North America	<18.1>	66.9	10.3	<11.7>	247.2 25.9
Europe	<3.0>	31.5	0.9	<19.7>	117.5 19.4
Other	<11.8>	30.8	3.3	<118.7>	117.6 63.8

5. Consolidated Segment information - Operating Segment

	FY2009 Results				
	Q4	YoY Changes		Full Year	YoY Changes
Net Sales	<5.6>	226.4	11.9	<13.1>	952.1 110.0
Pharmaceuticals	<5.6>	225.7	11.9	<13.1>	948.8 110.1
Domestic	<-1.6>	87.2	-1.4	<1.0>	421.1 4.4
Overseas	<12.7>	129.5	14.6	<29.4>	482.9 109.6
OTC drugs	<-14.1>	8.6	-1.4	<-7.4>	43.7 -3.5
Other	<-2.9>	0.8	0.0	<-3.3>	3.3 -0.1
Operating income	<->	5.4	14.6	<7.5>	95.5 6.6
Pharmaceuticals	<->	4.9	15.2	<8.4>	93.3 7.2
Other	<4.3>	0.5	0.0	<-0.2>	2.2 0.0

6. Consolidated Segment information - Geographic Segment

	FY2009 Results					
	Q4	YoY Changes		Full Year	YoY Changes	
Net Sales	<5.6>	100.0	226.4	11.9	<13.1>	100.0 952.1 110.0
Japan	<-3.1>	48.2	109.2	-3.5	<-1.9>	54.6 519.4 -10.3
North America	<24.1>	26.8	60.7	11.8	<16.6>	23.4 222.5 31.7
Europe	<6.7>	12.1	27.5	1.7	<28.2>	10.4 99.3 21.8
India	<-1.1>	6.7	15.1	-0.2	<292.8>	6.3 59.9 44.7
Other	<17.5>	6.2	14.0	2.1	<76.4>	5.4 51.0 22.1
Operating income	<->	5.4	14.6		<7.5>	95.5 6.6
Japan			-9.9			40.5
North America			7.7			47.1
Europe			3.0			9.1
India			6.3			4.5
Other			-0.2			3.3

7. Status of Major Companies

7-1. Daiichi Sankyo Co., Ltd.

	FY2009 Results					(Billions of yen)	
	Q4	Full Year	From Jan. Forecast	YoY Changes	FY08 Results ==> FY09 Results	FY2010 Forecast	YoY Changes
Total net sales of ethical pharmaceuticals	<-1.9> 84.5	<-1.4> 412.3	-2.7	5.6		<-0.7> 415.0	2.7
Olmotec <antihypertensive>	<-12.5> 16.2	<-20.0> 77.2	-0.8	12.9	Despite competitive market conditions, on the strength of antihypertensive effects and its efficacy for organic protection, sales continued to grow above the market growth rate resulting in a significant sales increase.	<-11.4> 86.0	8.8
Rezaltas <antihypertensive>	-	-	-	-	(Launched on April 16, 2010)	<-> 5.0	5.0
Calblock <antihypertensive>	<-4.7> 2.9	<-12.8> 13.7	-0.3	1.6	In addition to promotion of long acting antihypertensive effects, prescriptions grew due to its efficacy for renal protection.	<-2.3> 14.0	0.3
Artist <antihypertensive>	<-1.9> 5.0	<-6.5> 23.3	-0.7	1.4	Artist prescriptions increased mainly for cardiac conditions as the only beta-blocker indicated for the treatment of chronic heart failure.	<-3.5> 22.5	-0.8
Mevalotin <antihyperlipidemic agent>	<-14.7> 8.5	<-8.9> 46.2	-0.8	-4.5	Its clinical efficacy as a standard statin is being promoted but revenues are declining due to increasing prescriptions of generics and competition from strong statins.	<-19.9> 37.0	-9.2
Kremezin <treatment for chronic renal failure>	<-0.5> 2.8	<-4.7> 13.3	-0.7	0.6	Its clear position as oral adsorbent listed in practice guidelines for chronic kidney disease and the clinical efficacy of early administration led to increase in new patients.	<-2.6> 13.0	-0.3
Hanp <treatment for acute cardiac failure>	<-7.5> 2.3	<-3.0> 9.4	-0.1	0.3	While the market diminishes with the expansion in Diagnosis Procedure Combination (DPC), Hanp maintained its strong market position as first choice for treatment of acute heart failure and sales slightly increased.	<-10.0> 8.5	-0.9
Livalo <antihyperlipidemic agent>	<-10.5> 1.6	<-19.6> 7.3	-0.2	1.2	Sales increased leveraging the announcement of evidence of studies on Japanese and the growth of the strong statin market.	<-9.7> 8.0	0.7
Sunrythm <antiarrhythmic agent>	<-7.5> 2.3	<-1.3> 11.5	-0.5	-0.2	Although Sunrythm ensured its market position due to its competitive edge as the first choice prescription for patients with atrial fibrillation, its sales decreased slightly with the increase of generic prescriptions and due to the diminishing antiarrhythmic agent market.	<-8.6> 10.5	-1.0
Fastic <antidiabetic agent>	<-6.4> 1.0	<-0.9> 5.2	-0.3	0.0	Added indication of concomitant use with thiazolidinediones (TZDs). Sales were flat due to the expansion of competitive glinide agents and entry of DPP-4 inhibitor into the market.	<-3.2> 5.0	-0.2
Cravit <synthetic antibacterial agent>	<-17.5> 11.4	<-1.5> 43.6	3.6	0.6	Sales slightly increased following the launch of Cravit high-dose in July 2009 coinciding with its strong appeal as effective control against drug-resistant bacteria based on PK/PD theory under the sluggish market.	<-24.4> 33.0	-10.6
Loxonin <anti-inflammatory analgesic>	<-19.4> 9.9	<-21.4> 47.0	-3.0	8.3	While the market for Loxonin in oral form remains sluggish, Loxonin Poulitce and Loxonin Tape with superior efficacy and strong brand name contributed to sales increase.	<-8.6> 51.0	4.0
Urief <treatment for dysuria>	<-9.9> 2.0	<-14.3> 9.0	-0.5	1.1	Sales increased on the back of market growth and due to the increase in the number of prescriptions and hospitals using Urief.	<-27.3> 11.5	2.5
Zyrtec <antiallergic agent>	<-15.1> 3.0	<-2.7> 9.6	-0.4	0.3	Although the market was flat due to small amount of pollen dispersion, sales increased after obtaining indication for pediatric use in April 2009.	<-16.3> 8.0	-1.6
Omnipaque <contrast agent>	<-4.8> 5.5	<-3.7> 27.3	-0.7	-1.0	While Omnipaque secured top share by such as expanding its lineups to match treatment needs, sales declined due to increased prescriptions of generic drugs following the expansion of DPC.	<-15.6> 23.0	-4.3

7-2. Daiichi Sankyo Healthcare Co., Ltd

	FY2009 Results					(Billions of yen)	
	Q4	Full Year	From Jan. Forecast	YoY Changes	FY08 Results ==> FY09 Results	FY2010 Forecast	YoY Changes
Daiichi Sankyo Healthcare Co., Ltd	<-14.1> 8.6	<-7.4> 43.7	-4.3	-3.5		<-10.9> 48.5	4.8
LuLu Series	<12.8> 1.6	<1.5> 9.9	-1.6	0.1	Sales increased due to favorable sales of a new product <i>LuLu Attack EX</i> .	<16.8> 11.6	1.7
Gaster 10	<-31.1> 0.5	<-37.0> 2.1	-0.1	-1.2	Sales fell due to the impact of the revised Pharmaceutical Affairs Act resulting in a decrease in the number of drug stores who sell Category 1 OTC drugs.	<27.0> 2.6	0.6
Shin-Sankyo Ichoyaku series	<7.9> 0.8	<7.8> 3.5	-0.1	0.3	Sales increased due to steady sales of <i>Shin-Sankyo Ichoyaku Plus</i> .	<4.6> 3.7	0.2
Patecs series	<-11.6> 0.4	<-9.3> 2.4	-0.3	-0.2	Sales have fallen due to the increased market competition.	<4.4> 2.6	0.1
Transino	<96.4> 0.3	<-39.9> 0.9	0.1	-0.6	Sales fell due to the impact of the revised Pharmaceutical Affairs Act resulting in a decrease in the number of drug stores who sell Category 1 OTC drugs.	<56.0> 1.4	0.5

7-3. Daiichi Sankyo, Inc. (US)

	FY2009 Results					(Billions of yen)	
	Q4	Full Year	From Jan. Forecast	YoY Changes	FY08 Results ==> FY09 Results	FY2010 Forecast	YoY Changes
Daiichi Sankyo, Inc. (DSI)	<15.2> 32.1	<2.9> 133.0	-1.0	3.7		<9.0> 145.0	12.0
mil USD	<18.0> 354	<11.4> 1,433	-13	147		<12.5> 1,611	178
Benicar / Benicar HCT <antihypertensive>	<11.7> 21.9	<1.8> 88.9	0.9	1.6	While the growth rate of ARB market slowed down on a prescription basis, DSI has continued to actively promote Benicar / Benicar HCT, and achieved increase both on a new prescription basis and in sales (local currency) basis.	<0.6> 89.5	0.6
mil USD	<14.8> 242	<10.2> 958	8	89		<3.8> 994	37
Azor <antihypertensive>	<29.7> 2.9	<47.2> 12.8	-0.2	4.1	Promotional activities were implemented to ensure its position as a unique product and resulted to achieve higher growth rate than competitive products on a prescription basis.	<1.7> 13.0	0.2
mil USD	<35.4> 32	<59.4> 138	-3	51		<5.0> 144	7
Welchol <antihyperlipidemic / type 2 diabetes>	<28.2> 6.8	<12.4> 27.5	0.5	3.0	Enhanced promotional activities leveraging its attribute as the only therapy approved to treat patients with type 2 diabetes and primary hyperlipidemia. Welchol oral suspension also contributed to increase prescriptions.	<3.5> 28.5	1.0
mil USD	<31.4> 75	<21.7> 296	5	53		<6.8> 317	20
Effient (alliance revenue) <antiplatelet>	<> -1.1	<> 0.1	-	0.1	Formulary acceptance and hospital adoption steadily increased. Active promotional activities started in Jan. 2010 leveraging master visual aid. Further continuous efforts to gain new prescriptions will be made.		
mil USD	<> -11	<> 1	-	1			

Forecast of Effient is not disclosed.

As a result of reviewing the disclosure of alliance revenue of prasugrel in this reference data, the revised amount until Q3, ¥-1 bil (Previous: ¥1.1 bil, restated as ¥0.1 bil, revised amount: ¥-1 bil) is included in the results of Q4. Consolidated net sales etc. are correctly accounted for and remain unchanged.

7-4. Luitpold Pharmaceuticals, Inc. (US)

	FY2009 Results					FY08 Results ===> FY09 Results	(Billions of yen) FY2010 Forecast	
	Q4	Full Year	From Jan. Forecast	YoY Changes	Full Year		YoY Changes	
Luitpold Pharmaceuticals, Inc. (LPI)	<18.9>	<1.9>					<-9.8>	
mil USD	12.7	52.1	0.6	1.0		47.0	-5.1	
	<21.4>	<10.3>				<-6.9>		
	140	561	5	52		522	-39	
Venofor <treatment for iron deficiency anemia>	<17.0>	<0.3>					<-16.0>	
mil USD	8.0	32.2	1.2	0.1	Through an exclusive sublicensing agreement for the US dialysis market with Fresenius Medical Care, the largest dialysis chain company in the world, the share of Venofor in this company continued to increase. Sales increased steadily in the nondialysis markets where LPI strengthened promotional activities to hematology specialists and hospitals.	27.0	-5.2	
	<19.8>	<8.6>				<-13.4>		
	89	346	12	28		300	-46	

7-5. Daiichi Sankyo Europe GmbH

	FY2009 Results					FY08 Results ===> FY09 Results	(Billions of yen) FY2010 Forecast	
	Q4	Full Year	From Jan. Forecast	YoY Changes	Full Year		YoY Changes	
Daiichi Sankyo Europe GmbH (DSE)	<9.7>	<7.1>					<0.4>	
mil €	20.4	75.2	-1.8	5.0		75.5	0.3	
	<9.8>	<17.1>				<9.7>		
	161	574	-9	84		629	56	
Olmotec / Olmetec Plus <antihypertensive>	<17.7>	<6.5>					<2.7>	
mil €	11.4	39.9	-1.1	2.4	DSE strengthened promotional activities in major countries and sales of both Olmetec and Olmetec Plus steadily grew. Sales of joint sales partners also remained firm, and the overall growth exceeded the average growth rate of ARB market.	41.0	1.1	
	<17.2>	<16.5>				<12.3>		
	90	304	-6	43		342	37	
Sevikar <antihypertensive>	<156.5>	<189.3>					<50.0>	
mil €	2.0	6.3	0.8	4.1	First launched in Germany in January 2009, the number of European countries where Sevikar is available continued to increase. Sales have firmly expanded on the back of promotional activities emphasizing the Sevikar's safety as well as efficacy.	9.5	3.2	
	<166.6>	<216.5>				<64.0>		
	16	48	7	33		79	31	
Evista <treatment for osteoporosis>	<-4.6>	<-23.6>					<-12.7>	
mil €	2.1	9.2	-0.8	-2.8	After acquiring additional marketing rights from Eli Lilly and Company in February 2008, DSE now markets Evista in 34 European countries. Although DSE has gradually shifted to own company promotion in each country and taken steps to maintain the sales level, sales are trending downwards.	8.0	-1.2	
	<-10.1>	<-16.4>				<-4.6>		
	17	70	-6	-14		67	-3	

Alliance Revenue of Efient (Europe)

Efient <antiplatelet>	<<>	<<>					
mil USD	0.4	0.5	-	0.4	Launched promotional activities in UK and Germany in March 2009. Efient is now available in nine European countries and DSE is gearing towards expanding prescriptions.		
	<<>	<<>					
	4	5	-	5			

Alliance revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include such revenue.

Forecast of Efient is not disclosed.

7-6. Asia, South and Central America (ASCA)

	FY2009 Results					FY08 Results ==> FY09 Results	(Billions of yen)	
	Q4	Full Year	From Jan. Forecast	YoY Changes	FY2010 Forecast		Full Year	YoY Changes
ASCA Total	<27.5> 7.7	<12.1> 25.8	0.8	2.8	Increase by 25.1% excluding the forex impact.	<8.6> 28.0	2.2	
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<1.4> 0.9	<2.0> 4.1	0.2	0.1	Increase by 10.9% on a local currency basis. In addition to the sales increase of Cravit, enhanced promotion were made on DSSH products (Cefmetazon, Carbenin).	<-4.9> 3.9	-0.2	
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	<34.0> 1.5	<38.4> 5.3	0.3	1.5	Increase by 50.4% on a local currency basis. In addition to the expansion of DSSH promoted products, increased sales of Carbenin and Cefmetazon promoted by DSBJ, made a substantial contribution.	<26.7> 6.7	1.4	
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-4.5> 0.7	<-10.7> 3.1	-0.1	-0.4	Decrease by 2.0% on a local currency basis. Sales of Olmesartan increased. Sevikar was launched in August 2009. Price revision in Oct. 2009 had a negative impact of 22%.	<-0.5> 3.1	0.0	
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<38.9> 0.9	<13.7> 3.4	0.0	0.4	Increase by 26.2% on a local currency basis. In addition to the increased sales of Cravit and revenue from the copromotion of Olmetec, launch of Sevikar in Jun. 2009 have made a contribution.	<39.4> 4.7	1.3	
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<27.4> 0.3	<7.7> 0.9	-0.1	0.1	Increase by 15.9% on a local currency basis. In addition to the increased sales of Cravit following the launch of Cravit i.v. 750mg, sales of Mevalotin by DSTH contributed to the growth.	<55.1> 1.4	0.5	
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<18.4> 1.6	<-5.2> 4.7	0.6	-0.3	Increase by 14.9% on a local currency basis. The combination drug (Olmesartan and Amlodipine) has accelerated sales growth of Olmesartan franchise.	<19.0> 5.6	0.9	
Daiichi Sankyo Venezuela, S.A. (DSVE)	<76.3> 1.7	<47.9> 4.1	-0.1	1.3	Increase by 62.8% on a local currency basis. Increased sales of Olmesartan franchise contributed to the growth of DSVE.	<-30.6> 2.9	-1.3	

Sales of DSVE are expected to increase by more than 40% in local currency in FY2010, while sales will decrease in Japanese yen due to the impact of currency fluctuation.

7-7. Ranbaxy Laboratories Limited

	FY2009 Results					FY08 Results ==> FY09 Results	(Billions of yen)	
	Q4	Full Year	From Jan. Forecast	YoY Changes	FY2010 Forecast		Full Year	YoY Changes
Ranbaxy Laboratories Limited	<14.9> 44.4	<279.3> 146.6	-	107.9		<12.6> 165.0	18.4	

8. Number of Employees

	FY2008	FY2009	
	Mar-2009	Sep-2009	Mar-2010 [*]
Total Number of Employees	28,895	29,272	29,825
Japan	9,148	9,323	8,892
Overseas	19,747	19,949	20,933

	FY2008		FY2009			
	Mar-2009	Sales Reps	Sep-2009	Sales Reps	Mar-2010 [*]	Sales Reps
Total Number of Employees	28,895		29,272		29,825	
<Japan>						
Daiichi Sankyo Co., Ltd. (DS)	5,960	2,400	6,042	2,400	6,028	2,400
Daiichi Sankyo Healthcare Co., Ltd (DSHC)	401	150	396	150	391	150
<US>						
Daiichi Sankyo, Inc. (DSI)	2,875	1,800	2,933	1,800	2,940	1,800
Luitpold Pharmaceuticals, Inc. (LPI)	477	70	490	70	611	80
<Europe>						
Daiichi Sankyo Europe GmbH (DSE)	2,436	1,350	2,471	1,360	2,432	1,340
<Asia / Latin America>						
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	459	158	479	175	490	178
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	504	208	553	243	565	247
Daiichi Sankyo Taiwan Ltd. (DSTW)	158	69	161	68	163	70
Daiichi Sankyo Korea Co., Ltd. (DSKR)	98	49	97	49	98	50
Daiichi Sankyo (Thailand) Ltd. (DSTH)	44	18	45	18	54	30
Daiichi Sankyo Hong Kong Ltd. (DSHK)	7	-	7	-	7	-
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	292	112	312	117	307	119
Daiichi Sankyo Venezuela, S.A. (DSVE)	131	80	156	86	141	84

	FY2008	FY2009	
	Mar-2009	Sep-2009	Mar-2010 [*]
Ranbaxy Group	12,174	12,127	12,995

* For overseas subsidiaries with different fiscal year-ends, figures as of Dec-09 are shown

9. Major Management / Financial Indicators

	FY2008 Results		FY2009 Results		(Billions of yen)
	1st Half	Full Year	1st Half	Full Year	FY2010 Forecast Full Year
Management Indicators					
Dividend payout ratio (Consolidated)	83.9%	-	113.0%	100.9%	93.9%
Dividend on equity (DOE)	-	5.4%	-	4.9%	-
Earnings per share (EPS)	47.7 yen	-304.2yen	26.6yen	59.4yen	63.9 yen
Dividend per share	40.0 yen	80.0 yen	30.0 yen	60.0 yen	60.0 yen
Dividend payment (billions of yen)	28.1	56.3	21.1	42.2	-
Return on equity (ROE)	-	-20.5%	-	4.9%	-
Book value per share (BPS)	1,683.8 yen	1,226.0 yen	1,213.8 yen	1,215.6 yen	-
Equity ratio	83.9%	57.7%	58.5%	57.4%	-
Number of treasury stock purchased	15.0 million	15.0million	-	-	-
Treasury stock purchase (billions of yen)	45.8	45.8	-	-	-
Total number of common shares [*]	704 million	704 million	704 million	704 million	-
Share price at end of period	2,695 yen	1,648 yen	1,853 yen	1,751 yen	-
Market value (billions of yen)	1,897.3	1,160.2	1,304.4	1,232.6	-
Financial Indicators (billions of yen)					
Total assets	1,412.3	1,494.6	1,460.3	1,489.5	
Current assets	857.5	783.5	771.5	819.8	
Debt with interest	0.0	327.3	318.5	290.9	
Shareholder's equity	1,185.3	863.1	854.4	855.7	
CF from operating activities	18.8	78.4	39.6	130.2	
CF from investing activities	-198.0	-413.9	54.9	42.6	
CF from financial activities	-71.0	98.1	-42.0	-89.1	
Free cash flow ^{**}	-179.3	-335.5	94.5	172.9	
Cash and cash equivalents, end of year	192.1	177.8	227.6	259.2	
Liquidity on hand ^{***}	385.1	364.2	341.2	358.3	
Number of consolidated subsidiaries	43	98	96	99	

* excluding treasury stock

** CF from operating activities + CF from investing activities

*** Current deposits + marketable securities + investment securities, etc

10. Capital Expenditure and Depreciation Expense

	FY2008 Results		FY2009 Results		(Billions of yen)
	1st Half	Full Year	1st half	Full Year	FY2010 Forecast Full Year
Depreciation expense	19.3	40.6	22.0	45.9	48.5
Capital expenditure	7.7	19.6	14.0	29.7	45.0

11. Number of Shares Held and Shareholders by Category

	As of March 31, 2009			As of September 30, 2009			As of March 31, 2010		
	Number of shareholders	Number of shares (million)	%	Number of shareholders	Number of shares (million)	%	Number of shareholders	Number of shares (million)	%
Government and public	2	0	0.0%	2	0	0.0%	2	0	0.0%
Financial institutions	185	347	49.0%	188	326	46.1%	172	310	43.8%
Financial instruments firms	72	10	1.5%	86	19	2.7%	84	19	2.6%
Corporate investors	738	45	6.5%	800	46	6.5%	793	46	6.5%
Foreign investors	698	200	28.3%	672	199	28.3%	619	212	29.9%
individuals	75,205	99	14.0%	94,070	111	15.7%	98,454	116	16.4%
Treasury stock	1	5	0.7%	1	5	0.7%	1	5	0.7%
Total	76,901	708	100.0%	95,819	708	100.0%	100,125	708	100.0%

12. Consolidated Balance Sheets

<Assets>

(Billions of yen)

	2009.3.31		2010.3.31		Change	Details
		%		%		
Current assets	783.5	52.4	819.8	55.0	36.3	
Cash and time deposits	76.6		101.0		24.4	Liquidity on hand (cash and current deposits + marketable securities + investment securities) <u>Total ¥358.3 billion (¥ -5.9 billion from the end of fiscal 2008)</u>
Trade notes and accounts receivable	195.5		211.9		16.4	
Marketable securities	235.5		236.5		1.1	<Breakdown> Net gain: <u>¥ +41.9 billion</u> Dividends paid: <u>¥ -49.3 billion</u>
Inventories	139.5		143.2		3.8	Breakdown of inventories as of Mar. 2010 Merchandise and finished goods: ¥ 91.7 billion Work in process: ¥ 16.8 billion Raw materials and supplies: ¥ 34.7 billion
Deferred tax assets	76.7		87.0		10.2	
Other current assets	60.8		41.8		-19.0	Refund of income taxes paid in FY2008
Allowance for doubtful accounts	-1.0		-1.7		-0.7	
Non-current assets	711.1	47.6	669.8	45.0	-41.3	
Property, plant and equipment	250.1	16.7	249.5	16.8	-0.6	
Buildings and structures, net	132.7		126.6		-6.1	
Machinery, equipment and vehicles, net	46.0		44.5		-1.5	
Land	42.4		42.6		0.3	
Construction in progress	13.3		22.3		9.0	
Other, net	15.7		13.5		-2.2	
Intangible assets	192.6	12.9	180.9	12.1	-11.7	
Goodwill, net	77.4		73.8		-3.6	Amortization: U3 Pharma: <u>¥ -5.0 bil</u> , Ranbaxy: <u>¥ -2.4 bil</u>
Other intangible assets, net	115.2		107.1		-8.1	Amortization: Ranbaxy, and sales rights of Evista in Europe
Investments and other assets	268.4	18.0	239.3	16.1	-29.1	
Investment securities	153.7		137.0		-16.7	
Long-term loans	0.6		0.1		-0.5	
Prepaid pension costs	6.9		3.9		-3.0	
Deferred tax assets	91.6		81.8		-9.8	
Other assets	15.9		16.9		1.0	
Allowance for doubtful accounts	-0.3		-0.3		0.0	
Total assets	1,494.6	100.0	1,489.5	100.0	-5.1	

<Liabilities and Net Assets>

(Billions of yen)

	2009.3.31		2010.3.31		Change	Details
		%		%		
Liabilities	606.0	40.5	600.0	40.3	-6.0	
Current liabilities	508.5	34.0	268.8	18.0	-239.7	
Trade notes and accounts payable	59.4		66.5		7.1	
Short-term bank loans	264.3		20.0		-244.4	Change to long-term financing; bonds payable and Long-term bank loans
Income taxes payable	8.2		10.6		2.4	
Allowance for sales returns	0.6		0.6		0.0	
Allowance for sales rebates	2.7		1.4		-1.3	
Allowance for contingent losses	-		1.6		1.6	
Other current liabilities	173.3		168.1		-5.2	
Long-term liabilities	97.4	6.5	331.2	22.2	233.7	
Bonds payable	-		100.0		100.0	
Convertible bond-type bonds with subscription rights to shares	47.1		49.5		2.5	
Long-term bank loans	15.9		121.4		105.5	
Deferred tax liabilities	5.4		29.2		23.8	
Accrued employees' severance and retirement benefits	10.6		12.3		1.7	
Accrued directors' severance and retirement benefits	0.2		0.1		0.0	
Provision for environmental measures	0.1		-		-0.1	
Other long-term liabilities	18.2		18.6		0.4	
Net assets	888.6	59.5	889.5	59.7	0.9	
Shareholders' equity	894.5	59.8	887.0	59.6	-7.4	
Common stock	50.0		50.0		0.0	
Capital surplus	105.2		105.2		0.0	
Retained earnings	753.8		746.4		-7.4	Dividends paid: ¥ -49.3 bil Net income: ¥ +41.9 bil
Treasury stock, at cost	-14.6		-14.6		0.0	
Valuation and other adjustments	-31.4	-2.1	-31.3	-2.1	0.1	
Net unrealized gain on investment securities	19.9		27.5		7.6	
Deferred gains or losses on hedges	0.1		1.0		0.9	
Foreign currency translation adjustments	-51.4		-59.8		-8.4	
Subscription rights to shares	2.4	0.2	3.3	0.2	0.9	
Minority interests	23.2	1.6	30.5	2.0	7.3	
Total liabilities and net assets	1,494.6	100.0	1,489.5	100.0	-5.1	

13. Consolidated Statements of Cash Flows


(Billions of yen)

	FY2008	FY2009	Change	
Income before income taxes and minority interests	-308.3	97.4	405.6	
Depreciation	40.6	45.9	5.4	
Loss on impairment of long-lived assets	3.1	2.1	-1.0	
Amortization of goodwill	371.8	8.9	-362.9	FY2008: Goodwill lump sum write-down on investment in Ranbaxy
(Gain) loss on valuation of derivatives	20.5	-17.2	-37.7	
(Increase) decrease in prepaid pension costs	1.1	3.0	1.9	
Foreign exchange (gains) losses	10.4	-2.6	-13.0	
(Increase) decrease in trade notes and accounts receivable	4.7	-15.4	-20.0	
(Increase) decrease in inventories	-2.1	-2.8	-0.7	
Increase (decrease) in trade notes and accounts payable	-0.3	6.4	6.7	
Increase (decrease) in accounts payable and accrued expenses	3.5	6.2	2.7	
Income taxes paid	-58.6	-30.4	28.2	
Other, net	-7.9	28.6	36.5	FY2009: Refund of income taxes paid in FY2008
Cash flows from operating activities	78.4	130.2	51.9	
Net (increase) decrease in short-term operating assets	36.5	82.7	46.2	
(Acquisitions) / proceeds from sales of fixed assets	-42.3	-27.7	14.6	
(Acquisitions) / proceeds from sales of investment securities	-10.5	-0.1	10.3	
Purchases of investments in consolidated subsidiaries	-411.3	-15.9	395.3	FY2008: Investment in U3 Pharma and Ranbaxy
Other, net	13.7	3.7	-9.9	
Cash flows from investing activities	-413.9	42.6	456.5	
Net increase (decrease) in short-term bank loans and long-term debt	197.3	-139.4	-336.7	Decrease in short-term bank loans by the issuance of bonds
Proceeds from issuance of bonds	-	99.7	99.7	Issuance of 5-year, 10-year bonds (net of issue cost)
Purchases of treasury stock	-45.8	-0.0	45.8	
Dividends paid	-53.3	-49.3	4.0	
Other, net	-0.1	-0.2	0.0	
Cash flows from financing activities	98.1	-89.1	-187.2	
Effect of exchange rate changes on cash and cash equivalents	-29.1	-2.3	26.8	
Net increase (decrease) in cash and cash equivalents	-266.5	81.4	348.0	
Cash and cash equivalents, beginning of period	444.3	177.8	-266.6	
Increase (decrease) in cash and cash equivalents due to changes in scope of consolidation	-0.0	-	0.0	
Cash and cash equivalents, end of period	177.8	259.2	81.4	

(This page is intentionally left blank)

14. Major R&D Pipeline




Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

Therapeutic Area	Main Existing Product	Phase1	Phase2
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor/Sevikar Welchol Effient/Efient Olmetec Rezaltas Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrythm Bepricor	DB-772d (oral factor Xa inhibitor)	★CS-866CMB(JP) (Olmesartan, Hydrochlorothiazide combination) DU-176b(US/EU) (Edoxaban / post surgical VTE / oral factor Xa inhibitor) CS-747(JP) (Prasugrel / anti-platelet agent)
Glucose metabolic disorders	Welchol Fastic		CS-1036(JP/Asia) (glucose absorption inhibitor)
Cancer	Topotecin Krestin	U3-1287(US) (anti-HER3 antibody) CS-1008(JP) (Tigatuzumab / anti-DR5 antibody) <u>CS-7017(JP/Asia)</u> (PPAR γ activator)	CS-1008(US/EU) (Tigatuzumab / anti-DR5 antibody) CS-7017(US/EU) (PPAR γ activator) DE-766(JP) (Nimotuzumab / anti-EGFR antibody) ARQ 197(US/EU) (c-Met inhibitor)
Infectious diseases	Levaquin / Tavanic Banan Cravit	CS-8958(US/EU) (Laninamivir / anti-influenza / co-development with Biota) <u>CS-4771</u> (Sepsis)	
Bone/Joint diseases	Loxonin Mobic		
Immunological allergic diseases	Zyrtec	CS-0777 (immunomodulator)	SUN13834(US) (chymase inhibitor)
Others	Venofer Evoxac Omnipaque Omniscan Visipaque Sonazoid Feron Urief		SUN11031(US/EU) (Human ghrelin / cachexia) ★DD-723-B(JP) (Perflubutane / ultrasonic contrast agent)

★Additional indications, new formulations etc.

Change from the announcement in January 2010

- # New (underline) DU-176b(VTE / US/EU/JP/Asia / P3), CS-7017(PPAR γ activator / JP/Asia / P1), CS-4771(Sepsis / P1)
- # Change of Stage etc. DU-176b(post surgical VTE / JP / Application), CS-8958(treatment / JP / Application),
SUN Y7017(Alzheimer's type Dementia / JP / Application), CS-1036(glucose absorption inhibitor / JP/Asia / P2)
- # Withdrawal of Development etc. ★CS-866CMB(JP)

Phase3	Application
<p>★CS-747(US/EU) (Prasugrel / ACS-MM / anti-platelet agent)</p> <p>DU-176b(US/EU/JP/Asia) (Edoxaban / AF / oral factor Xa inhibitor)</p> <p><u>DU-176b(US/EU/JP/Asia)</u> (Edoxaban / VTE / oral factor Xa inhibitor)</p> 	<p>★CS-8635(US/EU) (Olmesartan, Amlodipine, Hydrochlorothiazide combination)</p> <p>DU-176b(JP) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)</p>
<p>★CS-8958(JP) (Laninamivir / prophylactic / anti-influenza)</p> 	<p>★Levofloxacin inj(JP) (new quinolone)</p> <p>CS-8958(JP) (Laninamivir / treatment / anti-influenza)</p>
<p>AMG 162(JP) (Denosumab / bone metastases of cancer, osteoporosis / anti-RANKL antibody)</p>	<p>★CS-600G(JP) (Loxoprofen / gel)</p>
<p>SUN11031(JP) (Human ghrelin / anorexia nervosa)</p> 	<p>KMD-3213(China) (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia)</p> <p>SUN Y7017(JP) (Memantine / Alzheimer's type Dementia)</p>

Cardiovascular diseases

【project after Phase II】

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-747	prasugrel	Oral	Anti-platelet agent	1) Acute coronary syndrome 2) Ischemic stroke	DAIICHI SANKYO, Ube Industries	US/EU JP	1) P3, 2) - 1) P2, 2) P2
<ul style="list-style-type: none"> Inhibition platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate(ADP) receptor on the platelet surface. Co-development with Eli Lilly in the US and EU, development by DAIICHI SANKYO in Japan In June, 2008, a new Phase3 trial started in US and EU for patients with acute coronary syndrome, not being managed with percutaneous coronary intervention (ACS-MM). [EU] Approved in Feb-2009 for ACS-PCI, launch in Mar-2009 in UK [US] Approved in Jul-2009 for ACS-PCI, launch in Aug-2009 [JP] P2 studies for elective PCI and ischemic stroke are on-going. 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DU-176b	edoxaban	Oral	Factor Xa inhibitor	1) Atrial fibrillation (AF) 2) Venous thromboembolism (VTE) 3) Post surgical VTE	DAIICHI SANKYO	US/EU JP	1)P3, 2)P3, 3) P2 1)P3, 2)P3, 3) App.
<ul style="list-style-type: none"> An oral anticoagulant that directly inhibits Xa factor playing an important role in the process when blood coagulates. An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials. No severe hepatotoxicity signals in pre-clinical and clinical trials Development by DAIICHI SANKYO globally <ul style="list-style-type: none"> - A P3 multi-national trial in AF started in Nov-2008. (ENGAGE AF-TIMI48) - A P3 multi-national trial for prevention of recurrent VTE in patients with deep-vein thrombosis and/or pulmonary embolism started in Jan-2010.(HOKUSAI VTE) Top line results for a Japanese P3 trial in VTE after surgery were announced in Dec-2009. [JP] Application for post surgical VTE: Mar-2010. 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-866CMB	olmesartan medoxomil hydrochlorothiazide	Oral	Angiotensin II receptor antagonist Diuretic	Hypertension	DAIICHI SANKYO	JP	Discontinued
<ul style="list-style-type: none"> Combination drug of olmesartan (angiotensin II receptor antagonist) and Hydrochlorothiazide(diuretic) LCM of olmesartan Discontinued due to less marketability of diuretic combination drug in Japan and the launch of new combination drug of olmesartan and azelnidipine(Ca channel blocker), REZALTAS[®] 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-8635	olmesartan medoxomil amlodipine besilate hydrochlorothiazide	Oral	Angiotensin II receptor antagonist Calcium channel blocker Diuretic	Hypertension	DAIICHI SANKYO	US/EU	Application
<ul style="list-style-type: none"> Combination drug of Olmesartan (angiotensin II receptor antagonist), Amlodipine(calcium channel blocker) and Hydrochlorothiazide(diuretic) LCM of Olmesartan [US] Application:Sep-2009 [EU] Application:Dec-2009 							

Diabetes mellitus

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-1036	-	Oral	Glucose absorption inhibitor	Diabetes mellitus	DAIICHI SANKYO	JP/Asia	P2
<ul style="list-style-type: none"> Inhibition of degrading starch and glucose absorption A P2 trial for Type 2 DM patients is ongoing 							

Cancer

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
ARQ 197	-	Oral	c-Met inhibitor	-	ArQule	US/EU	P2
<ul style="list-style-type: none"> c-Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction. Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc. Clinical studies are on-going for several types of cancer. 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	-	DAIICHI SANKYO	US/EU JP	P2 P1
<ul style="list-style-type: none"> A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5). DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells. Induces apoptosis of tumor cells expressing DR5 on the cell surface. Clinical studies are on-going for several types of cancer. 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	-	CIMYM Biosciences	JP	P2
<ul style="list-style-type: none"> A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR). Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies. Clinical studies are on-going for several types of cancer. 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-7017	-	Oral	PPAR-gamma activator	-	DAIICHI SANKYO	US/EU JP/Asia	P2 P1
<ul style="list-style-type: none"> Inhibits growth of tumor cells in vitro without killing those cells. Expected to be less toxic compared to standard chemotherapeutics. Clinical studies are on-going for several types of cancer. 							

Infectious diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, 1) Treatment, 2) Prophylactic	DAIICHI SANKYO	US/EU JP	P1 1) App., 2) P3
<ul style="list-style-type: none"> CS-8958 is a long-acting neuraminidase inhibitor that is expected to be used as single administration for treatment and once a week for prophylaxis. Co-development with Biota in the US and EU, development by DAIICHI SANKYO in Japan CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection. [JP] Application for treatment: Jan-2010 A new phase 3 trial for a prophylaxis indication was started in Japan in Nov-2009. 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
levofloxacin inj	levofloxacin	Injection	New quinolone	Bacterial infections	DAIICHI SANKYO	JP	Application
<ul style="list-style-type: none"> The drug inhibits bacterial DNA composition by inhibiting a DNA gyrase activity and a topoisomerase IV activity. New formulation (injection of levofloxacin) Application: Oct-2009 							

Immunological allergic diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 13834	-	Oral	Chymase inhibitor	Atopic Dermatitis	Asubio Pharma	US	P2
<ul style="list-style-type: none"> Inhibiting chymase, one of endogenous proteases, which is released from mast cells and involves allergic reaction. Expected to be an oral anti-atopic dermatitis drug with a novel mechanism of action. 							

Bone/Joint diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
AMG 162	denosumab	Injection	Anti-RANKL antibody	Osteoporosis Bone metastases of cancer	Amgen	JP	P3
<ul style="list-style-type: none"> Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling. July, 2007 In-licensed from Amgen P3 : Osteoporosis, completed enrollment P3 : Bone metastases of cancer, in preparation for NDA filing 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-600G	loxoprofen	Gel	Anti-inflammatory and analgesic	Osteoarthritis Muscle ache Algia after trauma	DAIICHI SANKYO	JP	Application
<ul style="list-style-type: none"> Mechanism of action: inhibition of prostaglandin composition/ Point of action: cyclooxygenase Development by DAIICHI SANKYO Loxoprofen gel formulation New formulation of LOXONIN 							

Others

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN Y7017	memantine	Oral	NMDA receptor antagonist	Dementia of Alzheimer type	Merz	JP	Application
<ul style="list-style-type: none"> Memantine, categorized as an antagonist of the NMDA receptor which is one of the Glutamate receptor subtypes in the central nervous system in mammals, possesses therapeutic action for dementia of Alzheimer type. The drug is expected to demonstrate effectivity in slowing down the progression of the disease by its neuroprotective action, which is distinct from cholinesterase inhibitors. Application: Feb-2010 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
KMD-3213	silodosin	Oral	Selective alpha 1A blocker	Treatment of dysuria associated with benign prostatic hyperplasia	Kissei	China	Application
<ul style="list-style-type: none"> An alpha1A blocker which effectively reduces urinary tract resistance and improves dysuria associated with benign prostatic hyperplasia. Reduces cardiovascular side effects due to its alpha1A selectivity. Silodosin is marketed in Japan as brand name of URIF by DAIICHI SANKYO and Kissei. Development by DAIICHI SANKYO in China Application: Dec-2008 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 11031	human ghrelin	Injection	-	Cachexia Anorexia Nervosa	Asubio Pharma	US/EU JP	P2 P3
<ul style="list-style-type: none"> Ghrelin is an endogenous peptide known as one-and-only peripheral appetite stimulator among all hormones discovered the relationship with feeding behavior up to now. In addition to it, ghrelin is a potent stimulator of growth hormone release. P2 study for cachexia in US/EU, and P3 study for anorexia nervosa are on-going. 							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DD-723-B	perflubutane	Injection	Ultrasonic contrast agent	Contrast for prostatic lesion Contrast for mammary lesion	GEHC	JP	P2
<ul style="list-style-type: none"> DD-723-B is marketed in Japan as a brand name of SONAZOID[®]. 							

<Historical Data>

Data available at www.daiichisankyo.com/ir/financial/index.html

1. Summary of Income Statement

(Billions of yen)

	FY2008			
	Q4		Full Year	
Net sales	<16.4> 100.0	214.5	<-4.3> 100.0	842.1
Cost of sales	29.7	63.6	25.5	214.4
Selling, general and administrative expenses	74.6	160.1	64.0	538.9
Research and development expenses	25.8	55.4	21.9	184.5
Other expenses	48.8	104.7	42.1	354.3
Operating income	<<-> -	<-9.2> -9.2	<-43.3> 10.6	88.9
Non-operating income		3.1		12.3
Non-operating expenses		31.9		46.0
Ordinary income	<<-> -	<-38.0> -38.0	<6.6> 6.6	55.2
Extraordinary gains		1.1		3.8
Extraordinary losses		5.9		367.2
Income before income taxes and minority interests	-	<-42.8> -42.8	-	<-308.3> -308.3
Net income	<<-> 38.4	<82.3> 82.3	<<-> -	<-215.5> -215.5

	FY2009									
	Q1		Q2		Q3		Q4		Full Year	
Net sales	<11.5> 100.0	227.1	<-20.2> 100.0	243.4	<15.3> 100.0	255.1	<-5.6> 100.0	226.4	<13.1> 100.0	952.1
Cost of sales	27.5	62.5	30.7	74.7	29.6	75.4	28.9	65.4	29.2	278.0
Selling, general and administrative expenses	60.7	137.8	59.4	144.6	55.1	140.5	68.7	155.6	60.8	578.6
Research and development expenses	19.9	45.1	20.1	49.0	18.7	47.6	24.3	55.1	20.7	196.8
Other expenses	40.8	92.7	39.3	95.6	36.4	92.9	44.4	100.5	40.1	381.8
Operating income	<-33.1> 11.8	26.8	<11.5> 9.9	24.1	<7.6> 15.4	39.2	<<-> 2.4	5.4	<7.5> 10.0	95.5
Non-operating income		3.9		10.9		4.3		9.1		28.2
Non-operating expenses		23.5		-10.1		5.1		2.1		20.6
Ordinary income	<-82.5> 3.2	7.2	<140.0> 18.5	45.1	<14.4> 15.0	38.4	<<-> 5.5	12.5	<-86.9> 10.8	103.1
Extraordinary gains		2.1		0.2		1.5		2.1		5.9
Extraordinary losses		0.7		0.3		2.5		8.1		11.6
Income before income taxes and minority interests	3.8	8.6	18.5	45.0	14.6	37.3	2.8	6.4	10.2	97.4
Net income	<<-> -	<-6.4> -6.4	<182.7> 10.3	25.1	<-> 8.1	20.6	<-96.8> 1.2	2.6	<<-> 4.4	41.9

2. Currency Rate

(yen)

	FY2008	
	Full Year	
USD / Yen (average)	100.5	
EUR / Yen (average)	143.5	
INR / Yen (average)	2.00	

	FY2009			
	Q1	Q2 YTD	Q3 YTD	Full Year
USD / Yen (average)	97.3	95.5	93.5	92.9
EUR / Yen (average)	132.6	133.2	133.0	131.2
INR / Yen (average)	1.89	1.95	1.95	1.95

3. Sales of Global Products

(Billions of yen)

	FY2008	
	Q4	Full Year
Olmesartan <antihypertensive>	<-9.1> 49.0	<8.0> 211.1
Olmotec (JPN)	<28.7> 14.4	<16.6> 64.4
Benicar / Benicar HCT (US)	<1.6> 19.6	<-0.6> 87.4
Azor (US)	<241.8> 2.3	<240.7> 8.7
Olmotec / Olmotec Plus* (EU)	<-13.6> 9.7	<-10.3> 37.5
Sevikar (EU)	<<-> 0.8	<<-> 2.2
Other subsidiaries / Export, etc	<-12.5> 2.2	<35.6> 11.0
Levofloxacin <synthetic antibacterial>	<-4.6> 22.6	<-10.2> 97.7
Cravit (JPN)	<-1.2> 9.7	<-9.2> 43.0
Export, etc	<7.6> 7.1	<-8.7> 31.1
Royalty	<-26.6> 4.0	<-17.6> 16.1
Other subsidiaries	<-2.6> 1.8	<-4.0> 7.5
Pravastatin <antihyperlipidemic>	<-15.3> 12.3	<-20.5> 60.8
Mevalotin (JPN)	<-14.3> 10.0	<-17.6> 50.7
Export	<-3.5> 0.7	<-36.6> 3.2
European subsidiaries*	<-43.9> 0.7	<-40.7> 4.0
Other subsidiaries	<7.1> 0.9	<7.2> 3.0

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Olmesartan <antihypertensive>	<10.5> 56.0	<10.2> 59.4	<12.3> 64.7	<19.0> 58.3	<12.9> 238.3
Olmotec (JPN)	<22.1> 19.0	<26.1> 19.8	<18.8> 22.2	<12.5> 16.2	<20.0> 77.2
Benicar / Benicar HCT (US)	<-5.6> 22.1	<0.5> 22.2	<2.0> 22.7	<11.7> 21.9	<1.8> 88.9
Azor (US)	<121.5> 3.0	<30.9> 3.2	<38.6> 3.6	<29.7> 2.9	<47.2> 12.8
Olmotec / Olmotec Plus* (EU)	<-0.2> 8.3	<-3.7> 10.0	<12.1> 10.2	<17.7> 11.4	<6.5> 39.9
Sevikar (EU)	<<-> 0.9	<<-> 1.2	<56.5> 2.2	<156.5> 2.0	<189.3> 6.3
Other subsidiaries / Export, etc	<29.9> 2.6	<-7.8> 3.1	<6.2> 3.7	<71.4> 3.7	<19.2> 13.1
Levofloxacin <synthetic antibacterial>	<-23.2> 19.8	<-0.3> 23.5	<-14.2> 22.1	<-3.5> 21.8	<-10.7> 87.2
Cravit (JPN)	<-6.8> 9.5	<26.7> 11.9	<-21.0> 10.8	<17.5> 11.4	<1.5> 43.6
Export, etc	<-49.6> 4.8	<-22.7> 6.4	<-17.6> 5.1	<-29.5> 5.0	<-31.5> 21.3
Royalty	<-9.9> 3.7	<-19.3> 3.2	<0.7> 4.1	<-8.8> 3.6	<-9.3> 14.6
Other subsidiaries	<-6.4> 1.8	<2.9> 2.0	<14.7> 2.1	<-2.2> 1.8	<2.2> 7.7
Pravastatin <antihyperlipidemic>	<-8.5> 14.7	<-5.2> 15.0	<-10.8> 14.8	<-14.9> 10.5	<-9.6> 55.0
Mevalotin (JPN)	<-8.3> 12.4	<-5.0> 12.4	<-9.1> 12.8	<-14.7> 8.5	<-8.9> 46.2
Export	<-37.6> 0.7	<23.3> 1.0	<-39.8> 0.4	<-41.4> 0.4	<-24.0> 2.4
European subsidiaries*	<11.3> 0.8	<-34.0> 0.8	<-37.7> 0.8	<-4.4> 0.7	<-21.2> 3.1
Other subsidiaries	<7.7> 0.8	<8.4> 0.8	<37.8> 0.8	<-4.1> 0.8	<10.5> 3.3

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. Three months results of Olmotec / Olmotec Plus and Pravastatin from Jan-07 to Mar-07 were ¥6.4 billion (€40 million) and ¥1.6 billion (€10 million), respectively.

	<->	<->
Prasugrel (alliance revenue) <antiplatelet>	0.03	0.03
Effient (US)	-	-
Effient (EU)	0.03	0.03

	<->	<->	<->	<->	<->
Prasugrel (alliance revenue) <antiplatelet>	0.0	1.0	0.3	-0.7	0.5
Effient (US)	-	1.0	0.2	-1.1	0.1
Effient (EU)	0.0	0.0	0.1	0.4	0.5

4. Overseas Sales

(Billions of yen)

	FY2008		FY2009				
	Q4	Full Year	Q1	Q2	Q3	Q4	Full Year
Overseas sales	<47.5>	<4.1>	<23.9>	<42.6>	<43.9>	<12.6>	<29.2>
	114.7	373.3	109.8	122.7	120.6	129.2	482.3
Overseas sales ratio	53.5%	44.3%	48.4%	50.4%	47.3%	57.0%	50.7%
North America	<21.7>	<0.6>	<1.1>	<16.6>	<11.5>	<18.1>	<11.7>
	56.6	221.3	58.9	62.5	58.9	66.9	247.2
Europe*	<37.0>	<0.3>	<21.3>	<27.6>	<32.9>	<3.0>	<19.7>
	30.5	98.2	27.2	29.7	29.2	31.5	117.5
Other	<206.7>	<33.6>	<197.4>	<232.9>	<259.4>	<11.8>	<118.7>
	27.6	53.8	23.7	30.5	32.5	30.8	117.6

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The net sales of DSE for the period from January to March 2007 was ¥14.1 billion.

5. Consolidated Segment information - Operating Segment

(Billions of yen)

	FY2008		FY2009				
	Q4	Full Year	Q1	Q2	Q3	Q4	Full Year
Net Sales	<16.4>	<4.3>	<11.5>	<20.2>	<15.3>	<5.6>	<13.1>
	214.5	842.1	227.1	243.4	255.1	226.4	952.1
Pharmaceuticals	<21.7>	<0.2>	<11.5>	<20.3>	<15.3>	<5.6>	<13.1>
	213.7	838.7	226.3	242.5	254.4	225.7	948.8
Domestic	<1.8>	<4.7>	<3.1>	<5.0>	<2.0>	<1.6>	<1.0>
	88.6	416.7	106.6	106.7	120.7	87.2	421.1
Overseas*	<46.7>	<5.9>	<23.9>	<42.5>	<44.5>	<12.7>	<29.4>
	114.9	373.3	109.9	122.2	121.3	129.5	482.9
OTC drugs	<6.5>	<6.2>	<6.9>	<2.1>	<8.2>	<14.1>	<7.4>
	10.1	47.2	9.5	13.5	12.1	8.6	43.7
Other	<90.7>	<91.3>	<2.6>	<3.5>	<4.4>	<2.9>	<3.3>
	0.8	3.4	0.8	1.0	0.7	0.8	3.3
Operating income	<>	<43.3>	<33.1>	<11.5>	<7.6>	<>	<7.5>
	-9.2	88.9	26.8	24.1	39.2	5.4	95.5
Pharmaceuticals	<>	<44.3>	<33.5>	<11.9>	<7.8>	<>	<8.4>
	-9.7	86.6	26.2	23.4	38.7	4.9	93.3
Other	-54	<116.2>	<1.3>	<0.6>	<3.1>	<4.3>	<0.2>
	0.5	2.2	0.5	0.7	0.5	0.5	2.2

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

6. Consolidated Segment information - Geographic Segment

(Billions of yen)

	FY2008		FY2009				
	Q4	Full Year	Q1	Q2	Q3	Q4	Full Year
Net Sales	<16.4>	<4.3>	<11.5>	<20.2>	<15.3>	<5.6>	<13.1>
	214.5	842.1	227.1	243.4	255.1	226.4	952.1
Japan	<8.4>	<11.4>	<3.1>	<1.8>	<3.3>	<3.1>	<1.9>
	112.7	529.8	128.5	135.4	146.4	109.2	519.4
North America	<31.7>	<7.2>	<7.0>	<20.4>	<15.6>	<24.1>	<16.6>
	48.9	190.8	54.2	54.5	53.1	60.7	222.5
Europe*	<41.8>	<0.7>	<48.1>	<32.4>	<37.8>	<6.7>	<28.2>
	25.8	77.4	22.5	24.5	24.8	27.5	99.3
India	<>	<>	<>	<>	<>	<-1.1>	<292.8>
	15.3	15.3	11.5	16.5	16.8	15.1	59.9
Other	<101.4>	<10.9>	<99.7>	<115.3>	<136.2>	<17.5>	<76.4>
	11.9	28.9	10.5	12.6	13.9	14.0	51.0
Operating income	<>	<43.3>	<33.1>	<11.5>	<7.6>	<>	<7.5>
	-9.2	88.9	26.8	24.1	39.2	5.4	95.5
Japan	-8.8	43.4	15.6	11.9	22.9	-9.9	40.5
North America	10.9	50.3	13.9	13.0	12.4	7.7	47.1
Europe*	4.0	5.8	1.2	1.9	3.1	3.0	9.1
India	-18.9	-18.9	-3.2	-1.7	3.1	6.3	4.5
Other	2.7	0.4	0.9	0.5	2.2	-0.2	3.3

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

7. Status of Major Companies

Data available at www.daiichisankyo.com/ir/financial/index.html

7-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2008	
	Q4	Full Year
Total net sales of ethical pharmaceuticals	<2.3> 86.2	<-4.8> 406.7
Cardiovascular disease	<-0.6> 49.9	<-4.8> 232.5
Olmetec <antihypertensive>	<-28.7> 14.4	<16.6> 64.4
Calblock <antihypertensive>	<-17.2> 2.8	<18.9> 12.1
Artist <antihypertensive>	<-6.8> 4.9	<-3.6> 21.9
Mevalotin <antihyperlipidemic agent>	<-14.3> 10.0	<-17.6> 50.7
Kremezin <treatment for chronic renal failure>	<5.3> 2.8	<-2.9> 12.8
Hanp <treatment for acute cardiac failure>	<-8.1> 2.2	<-6.2> 9.2
Livalo <antihyperlipidemic agent>	<-16.6> 1.4	<11.8> 6.1
Sunrhythm <antiarrhythmic agent>	<-0.3> 2.5	<-3.6> 11.6
Fastic <antidiabetic agent>	<-1.3> 1.1	<-1.2> 5.1
Infectious diseases / bone and joint diseases / immunological allergic diseases / urology	<4.6> 30.0	<-1.0> 137.4
Cravit <synthetic antibacterial agent>	<-1.2> 9.7	<-9.2> 43.0
Loxonin <anti-inflammatory analgesic>	<-12.3> 8.3	<15.1> 38.7
Mobic <anti-inflammatory analgesic>	<-18.3> 1.6	<-17.8> 8.4
Urief <treatment for dysuria>	<-60.5> 2.2	<46.0> 7.9
Zyrtec <antiallergic agent>	<-4.8> 3.5	<-14.1> 9.3
Contrast agents / cancer / gastric diseases	<-13.6> 10.1	<-17.5> 48.8
Omnipaque <contrast agent>	<-4.7> 5.7	<-9.1> 28.3
Topotecin <anticancer agent>	<-2.1> 1.4	<-0.9> 6.2

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Total net sales of ethical pharmaceuticals	<3.7> 104.6	<-5.3> 104.8	<-1.4> 118.4	<-1.9> 84.5	<-1.4> 412.3
Cardiovascular disease	<-3.8> 62.3	<-8.2> 61.9	<-3.0> 67.5	<-1.4> 49.2	<-3.6> 240.8
Olmetec <antihypertensive>	<-22.1> 19.0	<-26.1> 19.8	<18.8> 22.2	<12.5> 16.2	<-20.0> 77.2
Calblock <antihypertensive>	<-14.5> 3.5	<-18.9> 3.5	<12.5> 3.8	<4.7> 2.9	<-12.8> 13.7
Artist <antihypertensive>	<-6.3> 6.0	<-11.3> 5.9	<6.0> 6.4	<1.9> 5.0	<-6.5> 23.3
Mevalotin <antihyperlipidemic agent>	<-8.3> 12.4	<-5.0> 12.4	<-9.1> 12.8	<-14.7> 8.5	<-8.9> 46.2
Kremezin <treatment for chronic renal failure>	<-5.5> 3.4	<-8.8> 3.5	<4.3> 3.7	<-0.5> 2.8	<-4.7> 13.3
Hanp <treatment for acute cardiac failure>	<-1.5> 2.4	<-11.3> 2.1	<-4.8> 2.6	<-7.5> 2.3	<-3.0> 9.4
Livalo <antihyperlipidemic agent>	<-22.8> 1.8	<-25.9> 1.8	<18.8> 2.1	<10.5> 1.6	<-19.6> 7.3
Sunrhythm <antiarrhythmic agent>	<-1.2> 3.0	<-3.4> 3.0	<-0.8> 3.2	<-7.5> 2.3	<-1.3> 11.5
Fastic <antidiabetic agent>	<-1.8> 1.4	<-7.3> 1.4	<-0.1> 1.4	<-6.4> 1.0	<-0.9> 5.2
Infectious diseases / bone and joint diseases / immunological allergic diseases / urology	<-9.4> 33.7	<-16.4> 37.2	<0.2> 44.7	<-7.8> 32.4	<-7.7> 148.0
Cravit <synthetic antibacterial agent>	<-6.8> 9.5	<-26.7> 11.9	<-21.0> 10.8	<17.5> 11.4	<-1.5> 43.6
Loxonin <anti-inflammatory analgesic>	<-33.0> 11.2	<-19.7> 12.5	<16.0> 13.3	<19.4> 9.9	<-21.4> 47.0
Mobic <anti-inflammatory analgesic>	<-17.5> 2.0	<-8.9> 2.0	<-10.6> 2.0	<-24.2> 1.2	<-14.8> 7.2
Urief <treatment for dysuria>	<-26.6> 2.2	<-26.1> 2.2	<19.3> 2.6	<-9.9> 2.0	<-14.3> 9.0
Zyrtec <antiallergic agent>	<-18.4> 2.4	<-13.3> 1.8	<8.8> 2.4	<-15.1> 3.0	<-2.7> 9.6
Contrast agents / cancer / gastric diseases	<-2.9> 12.6	<-1.7> 12.7	<-8.7> 12.7	<-0.7> 10.1	<-1.5> 48.1
Omnipaque <contrast agent>	<-2.0> 7.1	<-3.4> 7.5	<-10.8> 7.1	<-4.8> 5.5	<-3.7> 27.3
Topotecin <anticancer agent>	<-5.6> 1.7	<-4.6> 1.6	<-14.2> 1.5	<-18.8> 1.1	<-5.5> 5.9

7-2. Daiichi Sankyo Healthcare Co., Ltd

(Billions of yen)

	FY2008	
	Q4	Full Year
Daiichi Sankyo Healthcare Co., Ltd	<-6.5> 10.1	<-6.2> 47.2
LuLu Series	<-6.9> 1.4	<-2.2> 9.8
Gaster 10	<-12.6> 0.7	<-5.5> 3.3
Shin-Sankyo Ichoyaku series	<-12.1> 0.7	<-5.2> 3.3
Patecs series	<-9.3> 0.4	<-10.4> 2.7
Transino	<-69.6> 0.1	<-41.4> 1.5

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Daiichi Sankyo Healthcare Co., Ltd	<-6.9> 9.5	<-2.1> 13.5	<-8.2> 12.1	<-14.1> 8.6	<-7.4> 43.7
LuLu Series	<-2.4> 1.2	<18.9> 4.3	<-19.5> 2.8	<12.8> 1.6	<-1.5> 9.9
Gaster 10	<-29.1> 0.5	<-45.7> 0.5	<-38.9> 0.6	<-31.1> 0.5	<-37.0> 2.1
Shin-Sankyo Ichoyaku series	<-26.3> 0.9	<-1.1> 0.9	<2.8> 1.0	<7.9> 0.8	<-7.8> 3.5
Patecs series	<-15.3> 0.9	<-17.8> 0.6	<-25.9> 0.5	<-11.6> 0.4	<-9.3> 2.4
Transino	<-62.3> 0.3	<-72.0> 0.2	<37.4> 0.2	<-96.4> 0.3	<-39.9> 0.9

7-3. Daiichi Sankyo, Inc. (US)

(Billions of yen)

	FY2008	
	Q4	Full Year
Daiichi Sankyo, Inc. (DSI)	<15.3> 27.9	<1.9> 129.3
mil USD	<27.9> 300	<15.8> 1,286
Benicar / Benicar HCT <antihypertensive>	<1.6> 19.6	<-0.6> 87.4
mil USD	<14.1> 210	<13.0> 869
Azor <antihypertensive>	<241.8> 2.3	<240.7> 8.7
mil USD	<285.1> 24	<287.2> 86
Welchol <antihyperlipidemic / type 2 diabetes>	<4.3> 5.3	<7.8> 24.5
mil USD	<17.8> 57	<22.5> 244
Effient (alliance revenue) <antiplatelet>	-	-
mil USD	-	-

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Daiichi Sankyo, Inc. (DSI)	<-11.2> 33.0	<5.6> 33.5	<5.8> 34.4	<15.2> 32.1	<2.9> 133.0
mil USD	<-4.6> 339	<21.7> 357	<13.4> 382	<18.0> 354	<11.4> 1,433
Benicar / Benicar HCT <antihypertensive>	<-5.6> 22.1	<0.5> 22.2	<2.0> 22.7	<11.7> 21.9	<1.8> 88.9
mil USD	<1.4> 227	<15.6> 237	<9.7> 253	<14.8> 242	<10.2> 958
Azor <antihypertensive>	<121.5> 3.0	<30.9> 3.2	<38.6> 3.6	<29.7> 2.9	<47.2> 12.8
mil USD	<138.0> 31	<49.3> 34	<50.9> 40	<35.4> 32	<59.4> 138
Welchol <antihyperlipidemic / type 2 diabetes>	<7.0> 6.9	<6.6> 6.5	<10.2> 7.3	<28.2> 6.8	<12.4> 27.5
mil USD	<14.9> 71	<22.8> 69	<18.7> 81	<31.4> 75	<21.7> 296
Effient (alliance revenue) <antiplatelet>	<>	<>	<>	<>	<>
mil USD	-	1.0	0.2	-1.1	0.1
	<>	<>	<>	<>	<>
	-	10	2	-11	1

7-4. Luitpold Pharmaceuticals, Inc. (US)

(Billions of yen)

	FY2008	
	Q4	Full Year
Luitpold Pharmaceuticals, Inc. (LPI)	<-17.8> 10.7	<0.1> 51.1
mil USD	<-5.7> 115	<13.8> 509
Venofer <treatment for iron deficiency anemia>	<-15.3> 6.9	<3.1> 32.0
mil USD	<-2.8> 74	<17.2> 319

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Luitpold Pharmaceuticals, Inc. (LPI)	<-1.1> 13.4	<-0.4> 13.5	<-6.4> 12.6	<18.9> 12.7	<1.9> 52.1
mil USD	<6.2> 137	<14.5> 144	<1.1> 140	<21.4> 140	<10.3> 561
Venofer <treatment for iron deficiency anemia>	<-3.9> 8.0	<-4.6> 8.1	<-4.1> 8.0	<17.0> 8.0	<0.3> 32.2
mil USD	<3.2> 82	<9.6> 87	<3.3> 89	<19.8> 89	<8.6> 346

7-5. Daiichi Sankyo Europe GmbH

(Billions of yen)

	FY2008	
	Q4	Full Year
Daiichi Sankyo Europe GmbH (DSE)	<2.4> 18.6	<-9.9> 70.3
mil €	<27.9> 147	<0.8> 490
Olmotec / Olmetec Plus <antihypertensive>	<-13.6> 9.7	<-10.3> 37.5
mil €	<8.5> 77	<0.3> 261
Sevikar <antihypertensive>	<> 0.8	<> 2.2
mil €	<> 6	<> 15
Mevalotin <antihyperlipidemic agent>	<-43.9> 0.7	<-40.7> 4.0
mil €	<-25.7> 6	<-33.7> 28
Evista <treatment for osteoporosis>	<57.8> 2.2	<128.5> 12.0
mil €	<111.8> 18	<155.6> 84

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Daiichi Sankyo Europe GmbH (DSE)	<14.1> 17.3	<-0.4> 18.4	<-6.1> 19.1	<9.7> 20.4	<7.1> 75.2
mil €	<40.6> 131	<20.8> 138	<5.9> 144	<9.8> 161	<17.1> 574
Olmotec / Olmetec Plus <antihypertensive>	<-0.2> 8.3	<-3.7> 10.0	<12.1> 10.2	<17.7> 11.4	<6.5> 39.9
mil €	<23.0> 63	<16.7> 74	<10.6> 77	<17.2> 90	<16.5> 304
Sevikar <antihypertensive>	<> 0.9	<> 1.2	<56.5> 2.2	<156.5> 2.0	<189.3> 6.3
mil €	<> 7	<> 9	<77.6> 16	<166.6> 16	<216.5> 48
Mevalotin <antihyperlipidemic agent>	<11.3> 0.8	<-34.0> 0.8	<-37.7> 0.8	<-4.4> 0.7	<-21.2> 3.1
mil €	<37.2> 6	<-20.0> 6	<-36.7> 6	<-9.2> 6	<-13.8> 24
Evista <treatment for osteoporosis>	<-24.9> 2.4	<-27.5> 2.6	<-31.1> 2.1	<-4.6> 2.1	<-23.6> 9.2
mil €	<-7.5> 18	<-12.2> 19	<-32.8> 16	<-10.1> 17	<-16.4> 70

* Following the change in fiscal year-end, FY2007 results for DSE, Olmetec / Olmetec Plus, Mevalotin and Evista are fifteen-months totals from Jan-07 to Mar-08.

Three months results from Jan-07 to Mar-07 were ¥14.1 billion (€89 million), ¥6.4 billion (€40 million), ¥1.6 billion (€10 million), and ¥1.0 billion (€6 million), respectively.

Alliance Revenue of Efient (Europe)

Effient <antiplatelet>	<>	<>
mil USD	0.03	0.03
	<>	<>
	0.3	0.3

	<>	<>	<>	<>	<>
	0.0	0.0	0.1	0.4	0.5
	<>	<>	<>	<>	<>
	0	0	1	4	5

* Alliance Revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include Alliance Revenue of Efient (Europe).

7-6. Asia, South and Central America (ASCA)

(Billions of yen)

	FY2008	
	Q4	Full Year
ASCA Total	<1.6> 6.0	<9.5> 23.0
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<-22.0> 0.9	<-1.3> 4.0
Daiichi Sankyo Pharmaceutical(Shanghai) Co., Ltd. (DSSH)	<126.2> 1.1	<69.0> 3.8
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-15.5> 0.8	<-5.4> 3.5
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<-19.7> 0.6	<-12.4> 3.0
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<-13.4> 0.2	<-1.4> 0.8
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<-4.2> 1.4	<13.6> 5.0
Daiichi Sankyo Venezuela, S.A. (DSVE)	<-9.8> 1.0	<19.0> 2.8

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
ASCA Total	<0.5> 5.3	<7.1> 6.3	<11.7> 6.6	<27.5> 7.7	<12.1> 25.8
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<-4.3> 1.0	<-7.6> 1.1	<-3.1> 1.1	<-1.4> 0.9	<-2.0> 4.1
Daiichi Sankyo Pharmaceutical(Shanghai) Co., Ltd. (DSSH)	<48.0> 1.1	<40.2> 1.3	<35.2> 1.4	<34.0> 1.5	<38.4> 5.3
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-8.6> 0.9	<-14.9> 0.8	<-14.4> 0.7	<-4.5> 0.7	<-10.7> 3.1
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<-15.6> 0.8	<-2.1> 0.9	<56.8> 0.9	<38.9> 0.9	<13.7> 3.4
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<-0.9> 0.2	<-0.4> 0.2	<4.2> 0.2	<27.4> 0.3	<-7.7> 0.9
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<-25.5> 0.8	<-12.7> 1.0	<-7.2> 1.3	<18.4> 1.6	<-5.2> 4.7
Daiichi Sankyo Venezuela, S.A. (DSVE)	<35.3> 0.7	<45.0> 0.9	<20.7> 0.8	<76.3> 1.7	<47.9> 4.1

7-7. Ranbaxy Laboratories Limited

(Billions of yen)

	FY2008	
	Q4	Full Year
Ranbaxy Laboratories Limited	<> 38.6	<> 38.6

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Ranbaxy Laboratories Limited	<> 29.7	<> 36.4	<> 36.0	<14.9> 44.4	<279.3> 146.6

7-8. ASCA & Ranbaxy's Sales of Global Products

(Billions of yen)

	FY2008	
	Q4	Full Year
Olmesartan <antihypertensive>	<38.4> 2.1	<74.2> 7.3
Levofloxacin <synthetic antibacterial>	<-2.6> 1.8	<-4.0> 7.5
Pravastatin <antihyperlipidemic>	<7.1> 0.9	<-7.2> 3.0

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Olmesartan <antihypertensive>	<42.4> 1.8	<25.7> 2.4	<22.7> 2.5	<50.7> 3.1	<34.8> 9.9
Levofloxacin <synthetic antibacterial>	<-6.4> 1.8	<-2.9> 2.0	<14.7> 2.1	<-2.2> 1.8	<-2.2> 7.7
Pravastatin <antihyperlipidemic>	<7.7> 0.8	<-8.4> 0.8	<37.8> 0.8	<-4.1> 0.8	<10.5> 3.3

(This page is intentionally left blank)

